Data as of Oct 24
| +0.44 / +15.71%|
ZIOPHARM Oncology, Inc. is a biopharmaceutical company currently in developmental stage that seeks to acquire, develop and commercialize, on its own or with commercial partners, a diverse portfolio of cancer therapies. The company also has a portfolio of small molecule drug candidates, which are no longer a strategic focus of its development activities for which the company is seeking partners to pursue further development and commercialization. It is currently focused on two clinical stage product candidates: Ad-RTS-IL-12 + veledimex and DC-RTS-IL-12 + veledimex. Ziopharm Oncology was founded on September 9, 2003 and is headquartered in Boston, MA.
|Jonathan J. Lewis||Chief Executive Officer & Director|
|Kevin G. Lafond||Chief Financial Officer, Treasurer, CAO & VP|
|J. Kris Piper||Vice President-Clinical Regulatory & Quality|
|Francois Lebel||SVP-Clinical Development & Medical Operations|
|Caesar J. Belbel||Secretary, Chief Legal Officer & Executive VP|